Engineering of bacterial strains and vectors for the production of plasmid DNA
Name
Prather_Engineering of bacterial.pdf
Size
300.01 KB
Format
Adobe PDF
Checksum (MD5)
97fe8cb92d9859cac77b56a9cf8130ed
Author(s)
Prather, Kristala L. Jones
Bower, Diana Morgan
Date Issued
February 2009
Journal
Applied Microbiology and Biotechnology
Publisher
Springer Berlin Heidelberg
Citation
D. Bower and K. Prather, “Engineering of bacterial strains and vectors for the production of plasmid DNA,” Applied Microbiology and Biotechnology, vol. 82, Apr. 2009, pp. 805-813.
Version
Author's final manuscript
Abstract
The demand for plasmid DNA (pDNA) is anticipated to increase significantly as DNA vaccines and non-viral gene therapies enter phase 3 clinical trials and are approved for use. This increased demand, along with renewed interest in pDNA as a therapeutic vector, has motivated research targeting the design of high-yield, cost-effective manufacturing processes. An important aspect of this research is engineering bacterial strains and plasmids that are specifically suited to the production of plasmid biopharmaceuticals. This review will survey recent innovations in strain and vector engineering that aim to improve plasmid stability, enhance product safety, increase yield, and facilitate downstream purification. While these innovations all seek to enhance pDNA production, they can vary in complexity from subtle alterations of the host genome or vector backbone to the investigation of non-traditional host strains for higher pDNA yields.
Subjects
gene therapy
strain engineering
Escherichia coli
DNA vaccines
plasmid DNA
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s00253-009-1889-8
